HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Lowers Price Target to $45
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $70 to $45.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $70 to $45.